Immune micro-environment analysis and establishment of response prediction model for PD-1 blockade immunotherapy in glioblastoma based on transcriptome deconvolution

被引:3
作者
Wong, David [1 ]
Yin, Yanhui [1 ]
机构
[1] Peking Univ, Sch Basic Med Sci, Dept Immunol, NHC Key Lab Med Immunol, Beijing, Peoples R China
关键词
Glioblastoma; PD-1; inhibitors; Transcriptome analysis; Tumor micro-environment; Drug response prediction model; CELL; EXPRESSION; CANCER;
D O I
10.1007/s00432-023-05026-0
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
PurposeOnly a small proportion of patients obtain survival benefit from PD-1 blockade immunotherapy due to the highly heterogeneous and suppressed immune micro-environment of GBM. We aimed at revealing the characteristics of tumor micro-environment (TME) of GBM related to response to PD-1 inhibitors and constructing a response prediction model for screening patients possibly benefit from PD-1 inhibitors.MethodsBased on the composition and expression profiles of cell subpopulations calculated by deconvoluting the GBM bulk RNA-seq, differentially expressed gene analysis and gene set enrichment analysis (GSEA) were performed to explore genes and pathways related to response to PD-1 inhibitors. Further by combining least absolute shrinkage and selection operator (LASSO) regression and expression correlation with PD-L1, the response prediction genes of PD-1 inhibitors were identified and the response prediction model was constructed through binary logistic regression.ResultsThe comparison of abundances of tumor infiltrating immune cells showed that the abundance of M0 macrophages of responders was lower, while the abundance of activated dendritic cells (DCs) was higher before PD-1 inhibitors treatment; the abundances of plasma cells and M0 macrophages of responders were lower after PD-1 inhibitors treatment. In addition, GSEA showed that the main up-regulation pathways in the tumor micro-environment of responders before PD-1 inhibitors treatment included the regulation of T-helper 1 type immune response, the positive regulation of natural killer cell-mediated cytotoxicity, p53 signaling pathway, homotypic cell-cell adhesion, etc., the main down-regulation pathways included the activation of microglia and myeloid leukocytes, Ras signaling pathway, etc. Afterward, ITGAX, LRRFIP1 and FMN1 were identified as the key response prediction genes of PD-1 inhibitors and the response prediction model based on them showed good predictive performance with potential value of clinical application in its validation and verification.ConclusionsITGAX, LRRFIP1 and FMN1 were identified as the response prediction genes of PD-1 inhibitors and the response prediction model based on them was proved to have potential clinical value.
引用
收藏
页码:11689 / 11703
页数:15
相关论文
共 18 条
[1]   Multidimensional Molecular Profiling of Metastatic Triple-Negative Breast Cancer and Immune Checkpoint Inhibitor Benefit [J].
Barroso-Sousa, Romualdo ;
Forman, Juliet ;
Collier, Katharine ;
Weber, Zachary T. ;
Jammihal, Tejas R. ;
Kao, Katrina Z. ;
Richardson, Edward T., III ;
Keenan, Tanya ;
Cohen, Ofir ;
Manos, Michael P. ;
Brennick, Ryan C. ;
Ott, Patrick A. ;
Hodi, F. Stephen ;
Dillon, Deborah A. ;
Attaya, Victoria ;
O'Meara, Tess ;
Lin, Nancy U. ;
Van Allen, Eliezer M. ;
Rodig, Scott ;
Winer, Eric P. ;
Mittendorf, Elizabeth A. ;
Wu, Catherine J. ;
Wagle, Nikhil ;
Stover, Daniel G. ;
Shukla, Sachet A. ;
Tolaney, Sara M. .
JCO PRECISION ONCOLOGY, 2022, 6
[2]   Challenges in glioblastoma research: focus on the tumor microenvironment [J].
Bikfalvi, Andreas ;
da Costa, Cristine Alves ;
Avril, Tony ;
Barnier, Jean-Vianney ;
Bauchet, Luc ;
Brisson, Lucie ;
Cartron, Pierre Francois ;
Castel, Helene ;
Chevet, Eric ;
Chneiweiss, Herve ;
Clavreul, Anne ;
Constantin, Bruno ;
Coronas, Valerie ;
Daubon, Thomas ;
Dontenwill, Monique ;
Ducray, Francois ;
Entz-Werle, Natacha ;
Figarella-Branger, Dominique ;
Fournier, Isabelle ;
Frenel, Jean-Sebastien ;
Gabut, Mathieu ;
Galli, Thierry ;
Gavard, Julie ;
Huberfeld, Gilles ;
Hugnot, Jean-Philippe ;
Idbaih, Ahmed ;
Junier, Marie-Pierre ;
Mathivet, Thomas ;
Menei, Philippe ;
Meyronet, David ;
Mirjolet, Celine ;
Morin, Fabrice ;
Mosser, Jean ;
Moyal, Elisabeth Cohen-Jonathan ;
Rousseau, Veronique ;
Salzet, Michel ;
Sanson, Marc ;
Seano, Giorgio ;
Tabouret, Emeline ;
Tchoghandjian, Aurelie ;
Turchi, Laurent ;
Vallette, Francois M. ;
Vats, Somya ;
Verreault, Maite ;
Virolle, Thierry .
TRENDS IN CANCER, 2023, 9 (01) :9-27
[3]   Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma [J].
Cloughesy, Timothy F. ;
Mochizuki, Aaron Y. ;
Orpilla, Joey R. ;
Hugo, Willy ;
Lee, Alexander H. ;
Davidson, Tom B. ;
Wang, Anthony C. ;
Ellingson, Benjamin M. ;
Rytlewski, Julie A. ;
Sanders, Catherine M. ;
Kawaguchi, Eric S. ;
Du, Lin ;
Li, Gang ;
Yong, William H. ;
Gaffey, Sarah C. ;
Cohen, Adam L. ;
Mellinghoff, Ingo K. ;
Lee, Eudocia Q. ;
Reardon, David A. ;
O'Brien, Barbara J. ;
Butowski, Nicholas A. ;
Nghiemphu, Phioanh L. ;
Clarke, Jennifer L. ;
Arrillaga-Romany, Isabel C. ;
Colman, Howard ;
Kaley, Thomas J. ;
De Groot, John F. ;
Liau, Linda M. ;
Wen, Patrick Y. ;
Prins, Robert M. .
NATURE MEDICINE, 2019, 25 (03) :477-+
[4]   Single-Cell RNA-Seq Analysis of Infiltrating Neoplastic Cells at the Migrating Front of Human Glioblastoma [J].
Darmanis, Spyros ;
Sloan, Steven A. ;
Croote, Derek ;
Mignardi, Marco ;
Chernikova, Sophia ;
Samghababi, Peyman ;
Zhang, Ye ;
Neff, Norma ;
Kowarsky, Mark ;
Caneda, Christine ;
Li, Gordon ;
Chang, Steven D. ;
Connolly, Ian David ;
Li, Yingmei ;
Barres, Ben A. ;
Gephart, Melanie Hayden ;
Quake, Stephen R. .
CELL REPORTS, 2017, 21 (05) :1399-1410
[5]   The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors [J].
Davis, Andrew A. ;
Patel, Vaibhav G. .
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7 (01)
[6]   CellMarker 2.0: an updated database of manually curated cell markers in human/mouse and web tools based on scRNA-seq data [J].
Hu, Congxue ;
Li, Tengyue ;
Xu, Yingqi ;
Zhang, Xinxin ;
Li, Feng ;
Bai, Jing ;
Chen, Jing ;
Jiang, Wenqi ;
Yang, Kaiyue ;
Ou, Qi ;
Li, Xia ;
Wang, Peng ;
Zhang, Yunpeng .
NUCLEIC ACIDS RESEARCH, 2023, 51 (D1) :D870-D876
[7]   PD-L1 Testing for Lung Cancer in 2019: Perspective From the IASLC Pathology Committee [J].
Lantuejoul, Sylvie ;
Sound-Tsao, Ming ;
Cooper, Wendy A. ;
Girard, Nicolas ;
Hirsch, Fred R. ;
Roden, Anja C. ;
Lopez-Rios, Fernando ;
Jain, Deepali ;
Chou, Teh-Ying ;
Motoi, Noriko ;
Kerr, Keith M. ;
Yatabe, Yasushi ;
Brambilla, Elisabeth ;
Longshore, John ;
Papotti, Mauro ;
Sholl, Lynette M. ;
Thunnissen, Erik ;
Rekhtman, Natasha ;
Borczuk, Alain ;
Bubendorf, Lukas ;
Minami, Yuko ;
Beasley, Mary Beth ;
Botling, Johan ;
Chen, Gang ;
Chung, Jin-Haeng ;
Dacic, Sanja ;
Hwang, David ;
Lin, Dongmei ;
Moreira, Andre ;
Nicholson, Andrew G. ;
Noguchi, Masayuki ;
Pelosi, Giuseppe ;
Poleri, Claudia ;
Travis, William ;
Yoshida, Akihiko ;
Daigneault, Jillian B. ;
Wistuba, Ignacio I. ;
Mino-Kenudson, Mari .
JOURNAL OF THORACIC ONCOLOGY, 2020, 15 (04) :499-519
[8]   Determining cell type abundance and expression from bulk tissues with digital cytometry [J].
Newman, Aaron M. ;
Steen, Chloe B. ;
Liu, Chih Long ;
Gentles, Andrew J. ;
Chaudhuri, Aadel A. ;
Scherer, Florian ;
Khodadoust, Michael S. ;
Esfahani, Mohammad S. ;
Luca, Bogdan A. ;
Steiner, David ;
Diehn, Maximilian ;
Alizadeh, Ash A. .
NATURE BIOTECHNOLOGY, 2019, 37 (07) :773-+
[9]  
Newman AM, 2015, NAT METHODS, V12, P453, DOI [10.1038/nmeth.3337, 10.1038/NMETH.3337]
[10]   Nivolumab plus radiotherapy with or without temozolomide in newly diagnosed glioblastoma: Results from exploratory phase I cohorts of CheckMate 143 [J].
Omuro, Antonio ;
Reardon, David A. ;
Sampson, John H. ;
Baehring, Joachim ;
Sahebjam, Solmaz ;
Cloughesy, Timothy F. ;
Chalamandaris, Alexandros-Georgios ;
Potter, Von ;
Butowski, Nicholas ;
Lim, Michael .
NEURO-ONCOLOGY ADVANCES, 2022, 4 (01)